Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Monopar Therapeutics Director's Dealing 2018

Sep 28, 2018

32883_dirs_2018-09-27_4517b6a7-6dce-4451-9bb3-185bce5f9a8e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2018-08-09

Reporting Person: Anderson Raymond (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-08-09 Stock options $6 A 26100 Acquired 2028-08-08 Common stock (26100) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common stock 1000 Direct

Footnotes

F1: Stock options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.